Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
Pulse Biosciences (PLSE) announced its nanosecond Pulsed Field Ablation (nsPFA) Percutaneous Electrode System will be featured at the North American Society for Interventional Thyroidology Annual Meeting in Washington D.C., January 31-February 1, 2025. The technology will be highlighted in both clinical science and video sessions.
The company recently obtained FDA 510(k) clearance for its nanosecond percutaneous electrode system for soft tissue ablation. According to CEO Paul LaViolette, the nsPFA technology's nonthermal mechanism limits scarring and fibrosis while sparing critical anatomical structures, making it potentially ideal for treating symptomatic benign thyroid nodules.
The scientific program includes presentations by Dr. Camila Mancera on clinical experience with nsPFA in thyroid nodule patients, and Dr. Stefano Spiezia presenting key nanopulse techniques. Pulse Biosciences will also maintain an exhibit booth at the Mayflower Hotel's East Room.
Pulse Biosciences (PLSE) ha annunciato che il suo sistema di elettrodi per ablazione a campo pulsatale nanosecondo (nsPFA) sarà presentato al Congresso Annuale della North American Society for Interventional Thyroidology che si terrà a Washington D.C. dal 31 gennaio al 1 febbraio 2025. La tecnologia sarà evidenziata sia nelle sessioni di scienza clinica che in quelle video.
L'azienda ha recentemente ottenuto l'approvazione FDA 510(k) per il suo sistema di elettrodi percutanei a nanosecondo per l'ablazione dei tessuti molli. Secondo il CEO Paul LaViolette, il meccanismo non termico della tecnologia nsPFA limita la formazione di cicatrici e fibrosi, preservando nel contempo le strutture anatomiche critiche, rendendola potenzialmente ideale per il trattamento di noduli tiroidei benigne sintomatici.
Il programma scientifico include presentazioni della Dr.ssa Camila Mancera sull'esperienza clinica con nsPFA nei pazienti con noduli tiroidei, e il Dr. Stefano Spiezia che presenterà tecniche chiave di nanopulse. Pulse Biosciences manterrà anche uno stand espositivo nella East Room del Mayflower Hotel.
Pulse Biosciences (PLSE) anunció que su sistema de electrodo por ablación de campo pulsado nanosegundo (nsPFA) será presentado en la reunión anual de la North American Society for Interventional Thyroidology que se llevará a cabo en Washington D.C. del 31 de enero al 1 de febrero de 2025. La tecnología se destacará tanto en sesiones de ciencia clínica como en sesiones de video.
La empresa obtuvo recientemente la autorización 510(k) de la FDA para su sistema de electrodo percutáneo de nanosegundos para ablación de tejidos blandos. Según el CEO Paul LaViolette, el mecanismo no térmico de la tecnología nsPFA limita la formación de cicatrices y fibrosis, al tiempo que preserva estructuras anatómicas críticas, lo que la hace potencialmente ideal para tratar nódulos tiroideos benignos sintomáticos.
El programa científico incluye presentaciones de la Dra. Camila Mancera sobre la experiencia clínica con nsPFA en pacientes con nódulos tiroideos, y el Dr. Stefano Spiezia presentando técnicas clave de nanopulso. Pulse Biosciences también tendrá un stand en el East Room del Mayflower Hotel.
Pulse Biosciences (PLSE)는 자사의 나노초 펄스 필드 절제(nsPFA) 경피 전극 시스템이 2025년 1월 31일부터 2월 1일까지 워싱턴 D.C.에서 열리는 북미 개입 갑상선학회 연례 회의에서 소개될 것이라고 발표했습니다. 이 기술은 임상 과학 세션과 비디오 세션 모두에서 강조됩니다.
회사는 최근 부드러운 조직 절제를 위한 나노초 경피 전극 시스템에 대해 FDA 510(k) 승인을 받았습니다. CEO인 Paul LaViolette에 따르면, nsPFA 기술의 비열적 메커니즘은 흉터와 섬유증을 제한하고 중요한 해부학적 구조를 보호하여 증상이 있는 양성 갑상선 결절 치료에 잠재적으로 이상적입니다.
과학 프로그램에는 갑상선 결절 환자에 대한 nsPFA의 임상 경험에 대한 Camila Mancera 박사의 발표와 주요 나노펄스 기술을 발표하는 Stefano Spiezia 박사가 포함됩니다. Pulse Biosciences는 메이플라워 호텔의 이스트 룸에서 전시 부스를 유지할 예정입니다.
Pulse Biosciences (PLSE) a annoncé que son système d'électrodes par ablation à champ pulsé nanoseconde (nsPFA) sera présenté lors de la réunion annuelle de la North American Society for Interventional Thyroidology qui se tiendra à Washington D.C. du 31 janvier au 1er février 2025. La technologie sera mise en avant tant dans les sessions de science clinique que dans les sessions vidéo.
L'entreprise a récemment obtenu l'approbation 510(k) de la FDA pour son système d'électrodes pércutanées à nanoseconde pour l'ablation des tissus mous. Selon le PDG Paul LaViolette, le mécanisme non thermique de la technologie nsPFA limite les cicatrices et la fibrose tout en épargnant les structures anatomiques critiques, ce qui la rend potentiellement idéale pour traiter les nodules thyroïdiens bénins symptomatiques.
Le programme scientifique comprend des présentations de Dr Camila Mancera sur l'expérience clinique avec nsPFA chez des patients atteints de nodules thyroïdiens, et Dr Stefano Spiezia présentant des techniques clés de nanopulsation. Pulse Biosciences maintiendra également un stand d'exposition dans la East Room de l'hôtel Mayflower.
Pulse Biosciences (PLSE) gab bekannt, dass ihr nanosekunden Pulsfeld-Ablations(nsPFA) perkutanes Elektrodensystem auf dem Jahrestreffen der North American Society for Interventional Thyroidology in Washington D.C. vom 31. Januar bis 1. Februar 2025 vorgestellt wird. Die Technologie wird sowohl in klinischen Wissenschaftssitzungen als auch in Videositzungen hervorgehoben.
Das Unternehmen hat kürzlich die FDA 510(k)-Zulassung für sein nanosekunden-perkutanes Elektrodensystem zur Ablation von Weichgewebe erhalten. Laut CEO Paul LaViolette begrenzt der nicht-thermische Mechanismus der nsPFA-Technologie Narbenbildung und Fibrose und schont dabei wichtige anatomische Strukturen, was sie potenziell ideal zur Behandlung symptomatischer benigner Schilddrüsenknoten macht.
Das wissenschaftliche Programm umfasst Präsentationen von Dr. Camila Mancera über klinische Erfahrungen mit nsPFA bei Patienten mit Schilddrüsenknoten und Dr. Stefano Spiezia, der Schlüsseltechniken des Nanopulses präsentiert. Pulse Biosciences wird auch einen Ausstellungsstand im East Room des Mayflower Hotels haben.
- Recent FDA 510(k) clearance obtained for soft tissue ablation
- Technology demonstrates tissue-sparing capabilities for critical structures
- None.
Nanosecond PFA Percutaneous Electrode System to be highlighted in clinical science and video sessions
“To obtain our initial FDA 510(k) clearance, we showed that our nanosecond percutaneous electrode system is safe and effective for soft tissue ablation. We believe the nonthermal mechanism of action of our nsPFA technology, which limits any scarring or fibrosis and spares critical anatomical structures like nerves and vessels, potentially makes nsPFA the ideal energy to treat symptomatic benign thyroid nodules,” said Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences. “We are thankful to all the clinicians who are currently choosing to investigate this application of our nsPFA technology, and we look forward to further assessing the benefits of treating symptomatic benign thyroid nodules in future clinical studies.”
Key Nanosecond PFA Scientific Programming
Friday, January 31st
-
4:40pm
- Early Clinical Experience with Nanosecond Pulsed Field Ablation in a Series of Patients with Benign Thyroid Nodules: Camila Mancera, MD
Saturday, February 1st
-
3:15pm
- Video Sessions: Key Techniques – Nanopulse: Presented by Stefano Spiezia, MD
Pulse Biosciences will also be hosting an exhibit booth on the show floor located in the East Room of the Mayflower Hotel.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nsPFA technology and its nsPFA Percutaneous Electrode System to ablate soft tissue with limited scarring or fibrosis and while sparing critical anatomical structures like nerves and vessels, statements concerning the Company’s expected product development efforts, including future clinical studies of its nsPFA Percutaneous Electrode System as a treatment for symptomatic benign thyroid nodules, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as symptomatic benign thyroid nodules, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the nsPFA Percutaneous Electrode System, Pulse Biosciences’ expectations, whether stated or implied, regarding its future clinical studies and regulatory submissions, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130313482/en/
Investors:
Pulse Biosciences, Inc.
Darrin Uecker, CTO or Kevin Danahy, CCO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
When will Pulse Biosciences (PLSE) present its nsPFA technology at the NASIT Annual Meeting 2025?
What FDA clearance has Pulse Biosciences (PLSE) received for its nanosecond PFA system?
What are the key benefits of PLSE's nsPFA technology for thyroid nodule treatment?